Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 317,733
  • Shares Outstanding, K 42,421
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,000 K
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10
Trade CRVS with:

Options Overview Details

View History
  • Implied Volatility 164.60%
  • Historical Volatility 328.69%
  • IV Percentile 77%
  • IV Rank 56.05%
  • IV High 232.10% on 06/28/21
  • IV Low 78.53% on 09/13/21
  • Put/Call Vol Ratio 0.75
  • Today's Volume 11,267
  • Volume Avg (30-Day) 9,195
  • Put/Call OI Ratio 1.44
  • Today's Open Interest 28,290
  • Open Int (30-Day) 7,617

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.35
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +12.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.97 +256.85%
on 08/24/21
9.54 -26.31%
on 09/21/21
+4.98 (+242.93%)
since 08/23/21
3-Month
1.86 +277.96%
on 08/20/21
9.54 -26.31%
on 09/21/21
+4.32 (+159.41%)
since 06/23/21
52-Week
1.86 +277.96%
on 08/20/21
9.54 -26.31%
on 09/21/21
+3.14 (+80.72%)
since 09/23/20

Most Recent Stories

More News
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants - Financial News Media

Palm Beach, FL - September 22, 2021 - FinancialNewsMedia.com News Commentary – The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development...

QBIO : 0.7400 (+13.71%)
CRVS : 7.03 (-6.14%)
MRNA : 454.60 (+3.15%)
SRNE : 8.08 (+1.13%)
CYDY : 2.3210 (-5.46%)
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants

PALM BEACH,  Fla., /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than to accelerate the discovery, development and manufacturing of antiviral medicines as part...

QBIO : 0.7400 (+13.71%)
CRVS : 7.03 (-6.14%)
MRNA : 454.60 (+3.15%)
SRNE : 8.08 (+1.13%)
CYDY : 2.3210 (-5.46%)
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

CRVS : 7.03 (-6.14%)
SPRO : 19.51 (+1.19%)
TAK : 17.15 (+0.88%)
MIRM : 20.18 (+3.70%)
Stocks Taking Center Stage on Wall Street (HLBZ,BLBX,NNVC,CRVS)

The SPY500 has bounced back over 150 points and looks like traders and investors are looking to buy the recent dip. Yesterday's massive sell off was a result of uncertainty over the future of Evergrande....

HLBZ : 23.00 (-5.74%)
GME : 191.24 (+0.58%)
AMC : 39.98 (-0.25%)
BLBX : 7.2500 (+3.57%)
NNVC : 5.24 (-8.87%)
CRVS : 7.03 (-6.14%)
AZN : 59.48 (+1.26%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 - Financial News Media

Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...

ONCY : 2.18 (+0.46%)
ONC.TO : 2.73 (-1.09%)
CRVS : 7.03 (-6.14%)
IPHA : 7.00 (-2.78%)
SURF : 7.98 (+2.05%)
CLVS : 4.61 (+3.83%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026

PALM BEACH,  Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective,...

ONCY : 2.18 (+0.46%)
ONC.TO : 2.73 (-1.09%)
CRVS : 7.03 (-6.14%)
IPHA : 7.00 (-2.78%)
SURF : 7.98 (+2.05%)
CLVS : 4.61 (+3.83%)
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options

Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.

CRVS : 7.03 (-6.14%)
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

NVS : 83.57 (+0.93%)
BGNE : 385.42 (-0.71%)
CRVS : 7.03 (-6.14%)
SPRO : 19.51 (+1.19%)
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal....

RDHL : 4.94 (+4.00%)
VTVT : 1.7700 (+4.12%)
CRVS : 7.03 (-6.14%)
SPRO : 19.51 (+1.19%)
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

ALNY : 186.95 (+2.60%)
VRTX : 185.09 (+0.44%)
CRVS : 7.03 (-6.14%)
SPRO : 19.51 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 8.33
2nd Resistance Point 7.88
1st Resistance Point 7.45
Last Price 7.03
1st Support Level 6.57
2nd Support Level 6.12
3rd Support Level 5.69

See More

52-Week High 9.54
Last Price 7.03
Fibonacci 61.8% 6.61
Fibonacci 50% 5.70
Fibonacci 38.2% 4.79
52-Week Low 1.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar